Wharton’s Jelly Mesenchymal Stromal Cells Support the Expansion of Cord Blood–derived CD34$^+$ Cells Mimicking a Hematopoietic Niche in a Direct Cell–cell Contact Culture System

Melania Lo Iacono¹, Eleonora Russo², Rita Anzalone³,₄, Elena Baiamonte¹, Giusi Alberti³, Aldo Gerbino², Aurelio Maggio¹, Giampiero La Rocca²,³, and Santina Acuto¹

Abstract

Wharton’s jelly mesenchymal stromal cells (WJ-MSCs) have been recently exploited as a feeder layer in coculture systems to expand umbilical cord blood–hematopoietic stem/progenitor cells (UCB-HSPCs). Here, we investigated the role of WJ-MSCs in supporting ex vivo UCB-HSPC expansion either when cultured in direct contact (DC) with WJ-MSCs or separated by a transwell system or in the presence of WJ-MSC–conditioned medium. We found, in short-term culture, a greater degree of expansion of UCB-CD34$^+$ cells in a DC system (15.7 ± 4.1-fold increase) with respect to the other conditions. Moreover, in DC, we evidenced two different CD34$^+$ cell populations (one floating and one adherent to WJ-MSCs) with different phenotypic and functional characteristics. Both multipotent CD34$^+$/CD38$^-$ and lineage-committed CD34$^+$/CD38$^+$ hematopoietic progenitors were expanded in a DC system. The former were significantly more represented in the adherent cell fraction than in the floating one (18.7 ± 11.2% vs. 9.7 ± 7.9% over the total CD34$^+$ cells). Short-term colony forming unit (CFU) assays showed that HSPCs adherent to the stromal layer were able to generate a higher frequency of immature colonies (CFU-granulocyte/macrophage and burst-forming unit erythroid/large colonies) with respect to the floating cells. In the attempt to identify molecules that may play a role in supporting the observed ex vivo HSPC growth, we performed secretome analyses. We found a number of proteins involved in the HSPC homing, self-renewal, and differentiation in all tested conditions. It is important to note that a set of sixteen proteins, which are only in part reported to be expressed in any hematopoietic niche, were exclusively found in the DC system secretome. In conclusion, WJ-MSCs allowed a significant ex vivo expansion of multipotent as well as committed HSPCs. This may be relevant for future clinical applications.

Keywords

hematopoietic stem and progenitor cell expansion, Wharton’s jelly mesenchymal stromal cells, hematopoietic niche, secretome, extracellular matrix

¹ Campus of Hematology F. and P. Cutino, Villa Sofia-Cervello Hospital, Palermo, Italy
² Section of Histology and Embryology, Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo, Italy
³ Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy
⁴ Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy

Submitted: June 14, 2017. Revised: August 30, 2017. Accepted: September 11, 2017.

Corresponding Author:
Giampiero La Rocca, Section of Histology and Embryology, Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, 90127 Palermo, Italy.
Emails: giampiero.larocca@unipa.it; giampylr@hotmail.com

Creative Commons CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Unrelated umbilical cord blood (UCB) transplantation has become one of the therapeutic options for pediatric patients with hematological malignancies and various genetic disorders. The easy availability, the higher tolerance to human leukocyte antigen (HLA)-mismatch, and the lower incidence of graft-versus-host disease (GvHD) make UCB an elective source of hematopoietic stem/progenitor cells (HSPCs) for cell transplantation compared to bone marrow (BM) and mobilized peripheral blood counterparts. More importantly, UCB-HSPCs have a higher frequency of progenitors with greater clonogenic potential compared to adult cells. Nonetheless, the number of HSPCs derived from 1 UCB unit is often not sufficient for transplantation in adult patients. In this regard, several attempts have been made to expand HSPCs by using specific culture media, supplemented with different combinations of cytokines and chemical compounds, and also by coculturing them with stromal feeder layers. The long-term fate of transplanted HSPCs greatly depends on their ability to adhere to the niche, with subsequent regulation of self-renewal versus differentiation states. All of these functions are regulated by cues provided in vivo by the hematopoietic niche cellular microenvironment. The niche of BM has been studied in both human and in vivo by the hematopoietic niche cellular microenvironment of a hematopoietic niche would improve the ex vivo HSPC expansion strategies. Recently, numerous studies have reported that MSCs from adult and perinatal sources have been used as feeder layers to expand and maintain the differentiated state of HSPCs. Nevertheless, the cellular and molecular mechanisms mediating these interactions are not fully elucidated. To date, few studies investigated how the MSCs from different sources, influenced the quantity and quality of expanded UCB-derived HSPCs in various coculture systems. Furthermore, studies are lacking with respect to a direct side-by-side comparison between cell–cell contact, noncontact, and expansion in standardized media, using UCB-derived HSPCs and MSCs. Wharton’s jelly (WJ) is an attractive source of MSCs. It originates from the extraembryonic mesoderm (EM) that constitutes the mesenchymal layer surrounding the amniotic cavity and yolk sac as well as the stroma of umbilical cord (UC) and placenta. EM has been shown to support embryonic and fetal hematopoietic niches. The WJ-derived MSCs (WJ-MSCs), isolated from UC matrix, may be an ideal candidate for creating an effective stromal feeder layer in coculture systems. These cells can be easily harvested and readily expanded to reach a confluent monolayer in a short time. Furthermore, WJ-MSCs produce several cytokines involved in the regulation of hematopoiesis, similarly to that observed in BM-MSCs. Key examples are interleukin-6 (IL-6) stem cell factor (SCF), Fms-related-tyrosine kinase-3 (Flt-3) ligand, and growth factors such as macrophage colony-stimulating factor (M-CSF), granulocyte colony-stimulating factor (G-CSF), and granulocyte/macrophage (GM) colony-stimulating factor (GM-CSF). It is important to note that the developmental history of WJ-MSCs further justifies a role for these cells in supporting hematopoiesis by establishing a functional niche-like environment for UCB-HSPCs. Indeed, WJ is part of the extraembryonic mesoderm, a tissue that arises early in the embryonic lining and is the very first hematopoietic niche (during the vitelline primitive hematopoiesis occurring in the wall of the yolk sac). Further ahead in human development, umbilical vessels and placenta have also been proposed as sites of hematopoiesis and storage of embryonic definitive CD34+ cells; this led to the concept of extraembryonic niches. In this work, we investigated the role of WJ-MSCs in supporting ex vivo UCB-CD34+ cell expansion. Cocultures were performed with CD34+ cells cultured either directly on a WJ-MSC layer or in the presence of WJ-derived conditioned medium (WJ-CM) or in a transwell system (TS). Phenotypical and functional characterization of the cultured CD34+ cells as well as systematical analysis of secretomes were performed in order to assess the role of this stromal cell population in the ex vivo expansion of HSPCs.

Materials and Methods

Isolation of WJ-MSCs

UCs (n = 12) were obtained at the Villa Sofia-Cervello Hospital, Palermo, Italy, after full-term births with written informed consent from mothers and treated in accordance with the tenets of the Declaration of Helsinki and local ethical regulations.

The UC was obtained at birth, after vaginal delivery or cesarean section, and stored in cold Hank’s balanced salt solution (HBSS) (Sigma-Aldrich, Milan, Italy), supplemented with 1% of antibiotic/antimycotic (penicillin/streptomycin, PAA Laboratories, Pasching, Austria). UCs were processed for cell isolation approximately 12 h from partum. The isolation procedure was performed at the tenets of the Declaration of Helsinki and local ethical regulations.

The UC was obtained at birth, after vaginal delivery or cesarean section, and stored in cold Hank’s balanced salt solution (HBSS) (Sigma-Aldrich, Milan, Italy), supplemented with 1% of antibiotic/antimycotic (penicillin/streptomycin, PAA Laboratories, Pasching, Austria). UCs were processed for cell isolation within 12 h from partum. The isolation procedure was performed as reported previously. Briefly, the collected UCs were cut into small pieces (of about 1 to 1.5 cm length) and sectioned longitudinally to expose the inner matrix, WJ, to the plastic surface of 6-well plates (6-well tissue-culture treated, CytOne). Each piece was completely covered with standard growth medium composed of Dulbecco’s modified Eagle’s medium (DMEM) low glucose (Gibco, Milan, Italy) supplemented with 10% heat inactivated fetal calf serum (FCS) (Gibco), 1% nonessential aminoacids (Sigma-Aldrich), and 1% penicillin/streptomycin (PAA Laboratories). The cord fragments were left in the culture medium for 15 d, with medium change every 2 d. After 15 d of culture, the cord fragments were removed from the wells, and cells attached to the plastic surface were cultured until they reached confluence. The subsequently passaged cells were collected by enzymatic treatment with 1X TrypLE Select (Gibco) and replated at 10,000 cells/cm².
**Phenotypical Characterization of WJ-MSCs**

WJ-MSCs were routinely phenotyped at the first and fourth passage by flow cytometry (FC-500 Beckman Coulter) according to the manufacturer’s instructions. The antibodies used were CD90-PC5, CD105-PC7, CD34-CD45-ECD (R-Phycoerythrin-Texas Red-X), HLA-DR-PE (Phycoerythrin), all supplied by Beckman Coulter, and CD73-FITC, supplied by BD Biosciences. Consistently, WJ-MSCs expressed the expected mesenchymal markers CD73, CD90, and CD105 and were negative for the hematopoietic markers CD34, CD45, and HLA-DR (data not shown). The ability of WJ-MSCs to differentiate toward osteogenic, adipogenic, and chondrogenic phenotypes was routinely assessed during culture passages as previously described19 (data not shown).

**UCB-CD34+ Cell Immunoselection and Subtyping**

UCB samples were collected at birth in isotonic saline solution supplemented with anticoagulant acid citrate dextrose A. CD34+ cells were immunoselected using a CliniMACS instrument (CD34 microbeads kit human, CliniMacs, Miltenyi Biotec) from the mononuclear cell fraction collected by Ficoll-Paque Plus density 1.077 gradient (GE Healthcare, Milan, Italy). The absolute numbers and the frequencies of CD34+ cells were measured in UCB samples at the time 0 and after 5 d of culture by flow cytometry analysis according to ISHAGE (International Society of Hematotherapy and Graft Engineering) protocol with a single platform method (Stem Kit, Beckman Coulter, Milan, Italy) that identifies the dual-positive CD45+/CD34+ cell population. To exclude dead cells from the analysis, 7-aminoactinomycin D (7-AAD) was used. The cells were cryopreserved in CS110 medium (STEMCELL Technologies) until the next use. Cell subtyping was performed by flow cytometry with a 4-color platform according to the manufacturer’s instructions. Cells were stained with the following monoclonal antibodies or with the corresponding isotype controls: fluorescein isothiocyanate (FITC)-conjugated CD45, ECD-conjugated CD34, and PC5-conjugated CD38, supplied by Beckman Coulter, and PE-conjugated CD133 (Miltenyi Biotech). Data were analyzed using the Cxp Cytometer analysis software and Kaluza software (Beckman Coulter).

**Coculture of WJ-MSCs and UCB-derived CD34+ cells**

All of the experiments were carried out in allogeneic systems. 5 × 10^4 WJ-MSCs at the fourth passage were seeded in each well of a 12-well plate (Costar, Corning) to reach a cell confluence of 70% to 80%. Cell growth was arrested with 20 µg/mL mitomycin C (Sigma-Aldrich) for 2.5 h at 37 °C in the presence of 5% CO2. After incubation, the WJ-MSCs were washed twice with phosphate buffered saline (PBS) and cultured in standard growth medium for 24 h before coculturing with CD34+ cells.

**WJ-CM Preparation**

WJ-MSCs at the fourth passage were used to produce a conditioned medium. Cells were grown in ACF medium until reaching a confluency of 70% to 80% and arrested with 20 µg/mL mitomycin C for 2.5 h at 37 °C in a 5% CO2 atmosphere. After cytostatic treatment, cells were washed twice with PBS and incubated for 48 h in ACF medium, supplemented with a CC110 cytokine cocktail. The medium was collected and centrifuged at 1,200 rpm for 8 min to remove the cellular debris and stored at −80 °C for the subsequent analyses.

**Immunocytochemical (ICC) Analysis**

After culturing, cells grown in chamber slides were washed with PBS and fixed in methanol for 20 min at −20 °C. Air-dried slides were then stored at −20 °C until use. For the ICC procedure, cells were permeabilized with 0.1% Triton X-100 in PBS (Sigma-Aldrich). After a subsequent rinse with PBS, immunocytochemistry (ICC) was performed using the ICC/IHC “Histostain Plus 3rd Gen IHC Detection” kit (Invitrogen). The primary antibodies used for this study were diluted with saponin 0.1% in PBS 1× and they were Fibronectin (Sigma-Aldrich), CD34 (Dako, Milan, Italy), and Vimentin (Dako). Nuclear counterstaining was obtained using hematoxylin (Dako).

In all culture conditions, 2.5 × 10^4 CD34+ cells/mL/well were grown in an animal component-free (ACF) medium (Stem Span™ ACF STEMCELL Technologies, Inc.) formulated for hematopoietic cell expansion, supplemented with a 1× cytokine cocktail (Stem Span™ CC110, STEMCELL Technologies, Inc.), and contained recombinant stem cell factor (SCF), Fms-related tyrosine kinase-3 ligand (Flt-3) and thrombopoietin (TPO). In particular, CD34+ cells were directly seeded on a WJ-MSC layer (DC system) or separated from the stromal feeders by a transwell permeable support (TS: 0.4 µm Polyester Membrane 12 mm Insert, 12-well Plate Tissue Culture Treated, Costar Corning) or in the presence of WJ-CM or in ACF medium alone (expansion medium [EM]). The evaluation of the CD34+ cell expansion was reported as fold increase after 5 d of culture with respect to time 0.
unit erythroid (BFU-E), colony forming unit granulocytes (CFU-G), colony forming unit monocytes, and colony forming unit granulocyte/erythroid/macrophage/megakaryocytes (CFU-GEMM).

**Statistical Analysis**

All statistical analyses were done using GraphPad Prism (version 7.02; https://www.graphpad.com/scientific-software/prism/). Results are presented as mean ± standard deviation (SD). To test statistical significance, a paired parametric t-test was used. Results were considered significant for P value <0.05.

**Sample Preparation for Secretome Analyses**

All media from different culture conditions were harvested, centrifuged (1,100 rpm at 4 °C for 5 min) and filtered through a 0.22-µm filter (Millipore) to remove cells and debris. The supernatants were dialyzed to remove and minimize charged ions and salts for the subsequent mass spectrometry (MS). After the dialysis, the samples were lyophilized and resuspended in ultrapure water in order to obtain a 100-fold protein concentration.

**In Solution Digestion**

The digestion step was performed adding Trypsin/Lys-C Mix (Promega) to 50 µg of proteins at a 25:1 protein:protease ratio (w/w), following the manufacturer’s instructions. Peptides, obtained after the digestion, were concentrated and desalted with Pierce C18 Spin Columns (Thermo Scientific). Then the samples were lyophilized and resuspended in ultrapure water in order to obtain a 100-fold protein concentration.

**High-performance Liquid Chromatography (HPLC) and Electro spray MS**

Reversed-phase HPLC separation and online mass spectrometry detection (HPLC-MS/MS) were performed using an UltiMate 3000 System ( Dionex) combined with Linear Trap Quadrupole (LTQ) Orbitrap XL™ Hybrid Ion Trap-orbitrap Mass Spectrometer (Thermo Fisher, Milan, Italy) via electrospray ionization (ESI) source. The chromatographic separation was carried out on a Hypersil Gold C18 column (15 cm × 2.1 mm, 1.9 µm). Sequential elution of peptides was accomplished using a flow rate of 50 µL min⁻¹ and a linear gradient from 98% solution A (0.1% formic acid) to 98% of solution B (80% acetonitrile, 0.08% formic acid) in 120 min. The gradient elution program was as follows: 2 min 98:2, 4 min 87:13; 95 min gradient from 87:13 to 50:50, 104 min 2:98, 109 min 2:98, 110 min 98:2, and 120 min 98:2 (A:B, v/v). The column temperature was set at 25 °C, and the sample tray temperature was maintained at 4 °C. For all experiments, a sample volume of 4 µL was loaded. For MS detection, the ESI source was operated in the positive mode and run with Xcalibur version 2.0 software (Thermo Fisher). High-purity nitrogen was used as the sheath, and the auxiliary gas and high-purity helium was used as the collision gas.

**Data Analysis**

The raw data were processed using Proteome Discoverer version 1.4 (Thermo Scientific). MS/MS spectra were sequentially searched with SequestHT and MS Amanda, both set against Homo sapiens database using the following parameters: full trypsin digest with maximum 2 missed cleavages; fixed modification carbamidomethylation of cysteine (+57.021 Da); variable modification oxidation of methionine (+15.995 Da); and phosphorylation of tyrosine, serine, and threonine (+79.966 Da). Precursor mass tolerance was 10 ppm and fragment ion tolerance was 0.8 Da. Peptide spectral matches were validated using percolator.

**In Silico Analysis**

In order to confirm the identified proteins, in silico analyses were carried out using the online ExPASy Proteomics Server (http://www.expasy.org) and the UniProt database (http://www.uniprot.org). For functional analysis of the proteomics data, the Database for Annotation, Visualization, and Integrated Discovery (version 6.8, https://david.ncifcrf.gov) was applied.

**Results**

**Phenotypic Characterization of WJ-MSCs and UCB-CD34⁺ Cells**

The MSC population derived from WJ was isolated by its ability to migrate and adhere to a plastic surface. Cells were subcultured for 4 passages prior to being used as feeders in coculture system. The morphological and phenotypical analyses, as well as the differentiative properties, were evaluated at the first and fourth passage. During culture, WJ-MSCs maintained the typical fibroblastoid morphology, with cell–cell contacts highlighted by processes extending between adjacent cells.

CD34⁺ cells from 12 UCB independent samples were enriched for CD34⁺ cells by immune selection to reach a purity of 90.2 ± 3.7% with a recovery of 65 ± 5%. The selected CD34⁺ cell population was subtyped for the presence of 2 surface markers, CD133 and CD38, that identify more primitive and committed hematopoietic progenitor cells, respectively. The frequency of CD34⁺/CD133⁻ cells in the uncultured cell population was 90.2 ± 5.8, and the frequency of CD34⁺/CD38⁻ cells was 40 ± 11%.

Phenotypic, functional, and proteomic analyses were performed after 5 d of WJ-MSC/CD34⁺ cell coculture; in our previous experiences, at this relatively short time of culture, the frequency of CD34⁺ cells within the total expanded cell population is only slightly decreased.
UCB-CD34⁺ Cell Expansion in Different Culture Systems

To investigate the role of WJ-MSCs to support in vitro expansion of HSPCs, the UCB-CD34⁺ cells were cultured either directly on WJ-MSC feeders (DC condition) or separated from feeder cells by TS, or in presence of conditioned medium derived from WJ-MSCs (WJ-CM), as well as in a standard EM alone. First, we assessed that 2.5 × 10⁴ cells/mL was the optimal seeding concentration to favor the cell expansion kinetic and that the presence of the 3 cytokines (SCF, TPO, and flt-3) known to support hematopoietic stem and progenitor cells was essential for cell growth in all tested culture conditions (data not shown). After 5 d of culture, the number of CD34⁺ cells significantly increased in all conditions with respect to time 0 (P < 0.0001); in particular, we observed a 15.7 ± 4.1-fold increase in the DC system, 9.5 ± 3.3 in WJ-CM, 8.4 ± 3.3 in EM, and 5 ± 2.2 in TS (Fig. 1). Notably, the DC system resulted in a superior expansion with respect to all the other culture conditions (P ≤ 0.001). At this time of culture, the frequency of CD34⁺ cells over the total hematopoietic cell population decreased by about 25% to 35% in the different culture conditions with respect to the uncultured samples (Fig. 1). Analogue results have already been reported in culture systems and expansion media very close to the conditions that we used in our experiments²⁰. This result shows that a portion of CD34⁺ cells are expanded while another portion of them differentiates.

The low expansion degree observed in TS was probably influenced by a mechanical hindrance of TS per se. Preliminary experiments (not shown) indicated that the TS is able to expand CD34⁺ cells only at very low concentrations, different from those used for this study.

In Vitro Interactions between CD34⁺ Cells and WJ-MSCs in the DC System

By phase-contrast microscopy, we observed within the direct coculture system that the expanded CD34⁺ cells localized in 2 distinct compartments: a floating cell population and another one adherent to the WJ-MSCs. Figure 2 shows that the majority of hematopoietic cells are floating in the medium. These cells can be easily harvested by medium aspiration. About one-third (36.9 ± 7.1% of the total expanded CD34⁺ cells in the DC condition) of the HSPCs are tightly bound to the stromal feeder cell layer. These adherent cells were harvested only after enzymatic treatment that breaks cell–cell or cell–matrix interactions. In fact as shown in Fig. 2, the adherent cells were either directly associated with WJ-MSCs or with the extracellular matrix (ECM) deposited by feeder cells. This is the first time that such an observation was made in a coculture system with WJ-MSCs as a feeder layer for UCB-HSPCs.

Immunocytochemistry analysis was performed to demonstrate the expression and localization of different molecules that mark specifically hematopoietic or stromal cells (Fig. 3). CD34 antibody was used to stain the HSPCs, showing the presence of the CD34⁺ cells over the WJ-MSCs that were negative for this marker (Fig. 3A). Vimentin, a typical cytoskeletal marker of MSCs, was localized in both HSPCs and WJ-MSCs (Fig. 3B and C), confirming literature data from our group and others.¹⁸,²¹ HSPCs showed pseudopodia-like protrusions indicating an active migratory activity over the culture surface. (Fig. 3D), a
Fig. 3. Microscopic demonstration of the expression of intracellular and extracellular molecules in the direct contact (DC) system. CD34⁺ cells belonging to the adherent fraction can be easily visualized in areas around Wharton’s jelly mesenchymal stromal cells (WJ-MSCs) as shown by their staining for anti-CD34 antibody (A). (B, C) Vimentin stains both WJ-MSCs and hematopoietic stem/progenitor cells (HSPCs). Higher magnification images (400×, C) show the close association between the WJ-MSC feeder layer and HSPCs. Apart from interacting with WJ-MSCs, HSPCs clearly show arrangements directed by the extracellular fibronectin polymerized by WJ-MSCs. (D) Fibronectin antibody shows cytoplasmic stain in WJ-MSCs but not in HSPCs. The protein is polymerized in an extracellular network with fibers localized both at the periphery of cells and on the culture surface. As indicated, HSPCs show pseudopodia-like protrusions (arrows) indicating a migratory activity over the vessel surface, which is covered with fibronectin filaments. The inset shows a higher magnification view of the cellular protrusions. (E) Extracellular fibronectin directs the adhesion of HSPCs (100×). (F) Higher magnification of the panel E (200×) showing nests of HSPCs localizing across fibronectin extracellular fibers and at the periphery of WJ-MSCs. (G) High-power view (400×) of panel F showing the interactions between HSPCs and the surrounding fibronectin-rich microenvironment. (H) The peripheral positive fibronectin stain in some HSPCs (with absence of cytoplasmic stain) suggesting a close receptor-mediated interaction. Magnifications: 100× (B, E), 200× (D, F), and 400× (A, G, H). Bar: 100 μm.
Table 1. Frequency of Primitive CD34⁺ Subtypes over the Total CD34⁺ Cells.

|                    | DC System          |
|--------------------|--------------------|
|                    | Uncultured Cells   | Floating Cells | Adherent Cells | WJ-CM | TS | EM |
| CD34⁺/CD38⁻, %     | 40.2 ± 9.2         | 9.7 ± 7.9      | 18.7 ± 11.2   | 52.9 ± 9.0 | 81.9 ± 5.8 | 89.2 ± 4.8 |
| CD34⁺/CD133⁺, %    | 90.2 ± 5.8         | 84.4 ± 6.6     | 84.0 ± 4.8    | 82.9 ± 8.5 | 79.9 ± 9.2 | 79.9 ± 8.1 |

Note: Results are reported as mean ± SD. DC = direct contact; WJ-CM = Wharton jelly–conditioned medium; TS = transwell system; EM = expansion medium.

Table 2. Frequency of ColoniesGenerated from CD34⁺ Cells Cultured in Direct Contact System.

| Colonies                              | DC System          |
|---------------------------------------|--------------------|
|                                       | Floating Cells | Adherent Cells | P Values |
| % CFU-GM + BFU-E/total colonies       | 35.0 ± 14       | 46.8 ± 13.9   | 0.007    |
| % CFU-GEMM/total colonies             | 0.5 ± 0.5       | 3.5 ± 1.3     | 0.0001   |
| % BFU-E(L)/total BFU-E colonies       | 19.0 ± 6.3      | 37.0 ± 14.7   | 0.013    |

Note: Results are reported as mean ± SD. DC = direct contact; CFU-GM = colony forming units–granulocyte/macrophage; BFU-E = burst-forming units–erythroid; BFU-E(L) = intermediate/large burst-forming units–erythroid; CFU-GEMM = colony forming units–granulocyte/erythroid/macrophage/megakaryocytes.

datum already reported in a similar coculture system where CD34⁺ cells were cocultured with WJ-MSCs²⁰. Fibronectin was expressed exclusively by WJ-MSCs (Fig. 3D-H). The cells showed an intense cytoplasmic staining according to their ability to produce and polymerize extracellular matrix molecules. Interestingly, fibronectin was localized extracellularly both at the periphery of WJ-MSCs and over the glass culture surface. This provided means for CD34⁺ cells to attach firmly to both WJ-MSCs and the culture slide. This is particularly evident in Fig. 3E-G showing that the arrangement of CD34⁺ cells follows the direction of the extracellular fibronectin fibers. High-power field images (Fig. 3H) suggest a close association between extracellular fibronectin and CD34⁺ cells, giving the impression of a positive staining at the membrane of the cells, which is however not matched by the expected cytoplasmic stain of cells actively synthesizing the molecule. Therefore, this suggests that CD34⁺ cells closely interact with fibronectin via receptor-mediated interaction.

**Subtyping of Expanded CD34⁺ Cells**

The frequencies of CD34⁺/CD133⁺ and CD34⁺/CD38⁻ subpopulations that identify early progenitor cells were measured in all culture conditions and within the 2 hematopoietic cell fractions of the DC system. After 5 d of culture, the frequency of CD34⁺/CD133⁺ progenitor cells was slightly decreased compared to the uncultured samples in all conditions and also within the 2 cell populations of the DC system (P ≤ 0.0377; Table 1).

Differences in the coexpression of the CD38 marker, which discriminate committed (CD34⁺/CD38⁻) from multipotent (CD34⁺/CD38⁺) progenitors²², were observed between CD34⁺ cells grown in direct contact with WJ-MSCs and all the other conditions. In particular, the frequency of the CD34⁺/CD38⁻ subpopulation over the total CD34⁺ cells was significantly increased in both EM and TS with respect to that of uncultured UCB-CD34⁺ cells. In particular, we observed a 2-fold increase in both EM and TS (P < 0.0001) and a 1.3-fold in WJ-CM (P = 0.0074; Table 1). Conversely, in the DC system, the frequency of multipotent progenitor cells decreased in both floating and adherent compartments when compared to the uncultured cells (P ≤ 0.0003). This decline was observed to a lesser extent in the adherent cell fraction (2-fold decrease) than in the floating cells (Table 1). These results highlighted that the cell–cell contact greatly favored the production of committed hematopoietic progenitors with respect to the other tested culture conditions. Notably, in the DC condition, the CD34⁺ cells adherent to the stromal layer comprised a higher percentage of early primitive cells when compared to the respective floating compartment (18.7 ± 11.2% vs. 9.7 ± 7.9%, P < 0.0001). In terms of absolute numbers, the CD34⁺/CD38⁻ early progenitors were found expanded in the DC culture system after 5 d; in particular, we observed a 2-fold increase in the floating cell population and a 3-fold increase in the adherent one (data not shown).

Overall, these data highlighted that cell–cell contact promoted both proliferation and differentiation of HSPCs resembling the main features of a hematopoietic niche. Similar results have been reported by Jing and colleagues who performed cocultures of mobilized peripheral blood-derived CD34⁺ cells over a feeder layer of BM-MSCs. The authors suggested that the hematopoietic cells beneath MSCs featured the low proliferation rate and displayed the markers of an immature phenotype²³.
Table 3. Hematopoiesis-regulating Molecules Identified in the Media of Different Culture Conditions.

| Molecules | Accession Number | Culture Condition | Role in Hematopoiesis | Hematopoietic niche | References |
|-----------|------------------|-------------------|------------------------|---------------------|------------|
| Secreted molecules | | | | | |
| ADAMTS9 | Q9P2N4 | TS1 | ECM remodeling | BM and umbilical cord | 24 |
| α Fetoprotein | P02771 | DC | Apoptosis prevention | Yolk sac, fetal liver, and placenta | 25 and 26 |
| α-2-HS glycoprotein | P02765 | EM, WJ-CM, TS1, TS2, and DC | Negative regulation of osteogenesis and TGF-β antagonist | BM, umbilical cord, fetal liver, and all MSC-derived tissue | 27 and 28 |
| Collagen α-1 (I) chain | P02452 | WJ-CM, TS2, and DC | Ossification, osteoblast differentiation, and regulation of adhesion | BM and umbilical cord | 29–31 |
| Collagen α-1 (III) chain | P02461 | DC | Osteoblastogenesis and immune regulation | BM and umbilical cord | 32–34 |
| Collagen α-2 (I) chain | P08123 | WJ-CM, TS2, and DC | Ossification, osteoblast differentiation, and regulation of adhesion | BM and umbilical cord | 29 and 30 |
| Collagen α-6 (VI) chain | A6NM7Z | DC | Cell adhesion, regulation of cell differentiation, inhibition of apoptosis, and oxidative damage | BM and umbilical cord | 29 and 35 |
| Fibronectin | P02751 | WJ-CM, TS2, and DC | Cell adhesion, migration, growth, differentiation, and bone matrix formation | BM and placenta | 34 and 35 |
| FREM3 | P0C091 | DC | Cell adhesion | BM | 36 |
| Glypican 4 | Q75487 | TS1 | Cell–cell interaction and control of cell growth and differentiation | BM | 37 |
| Hypoxia upregulated protein-1/GRP170 | Q9Y4L1 | DC | Stress-induced chaperone | BM and placenta | 36 and 38 |
| Lactotransferrin | E7EQ82 | DC | Promotion of lymphocyte maturation, regulation of myelopoiesis, regulation of bone metabolism, and anti-inflammatory and immunoregulatory proprieties | BM | 39–41 |
| MMP8 | P22894 | TS1 | ECM remodeling and hematopoietic stem/progenitor cells mobilization | BM | 42 |
| PAI-1 | P05121 | EM and DC | ECM remodeling and regulation of hematopoietic regeneration | BM | 43 |
| Serine carboxypeptidase I | Q46840 | DC | ECM remodeling | BM | 44 and 45 |
| SPARC | P09486 | WJ-CM, TS1, TS2, and DC | ECM remodeling; bone remodeling; osteoblast formation, maturation, and survival; B lymphopoiesis stimulation; development of erythroid progenitors; and angiogenesis | BM (endosteal niche) | 46–48 |
| TIMP-1 | P01033 | WJ-CM, TS2, and DC | ECM remodeling; proliferation, apoptosis, differentiation, and angiogenesis; and regulation of erythroid cells proliferation | BM, umbilical cord, and placenta | 49 and 50 |
| Transforming growth factor-β-induced protein ig-h3 | Q15582 | WJ-CM and DC | Cell adhesion and migration | BM and fetal liver | 51–53 |
| Wnt-4 | Q56705 | TS1 | Osteogenesis, HSC proliferation, myeloid, and B lymphoid development | BM | 54 and 55 |
| Wnt-6 | Q9Y6F9 | DC | Osteoblastogenesis and macrophage proliferation and differentiation | BM | 56 |
| Membrane molecules | | | | | |
| Cadherin-23 | Q9H251 | DC | Cell–cell interaction | BM | 36 |
| CD109/150 kDa TGF-β-1 binding protein | Q6YHK3 | DC | Negative regulation of TGF-β responses and osteoclastogenesis | BM (CD34<sup>+</sup>) | 57 and 58 |
| Integrin α4 | P13612 | DC | Cell adhesion and homing and HSC growth | BM | 59 |
| Interleukin 23 receptor | Q59205 | WJ-CM | Stimulates T cells, NK cells, and possibly certain macrophage/myeloid cells | BM | 60 |
| Lysophosphatidic acid receptor 1 | Q92633 | DC | Cell migration; regulator of migration, growth, and survival of myeloid progenitors; CD34<sup>+</sup> survival; regulation of primitive hematopoiesis; and osteoblast differentiation | BM, yolk sac, and placenta | 61 and 62 |
| Notch-2 | Q04721 | DC | Inhibition of granulocytic differentiation, negative role in megakaryopoiesis, enhance of erythrocytic differentiation, suppressing osteoblastogenesis, and promotion of osteoclastogenesis | BM (hematopoietic progenitors and CD34<sup>+</sup>) and yolk sac osteoclastogenesis | 63–65 |
| Protocadherin 8 | Q95206 | DC | Cell–cell interaction and cell sorting movements | Placenta exosomes | 66 |
| Protocadherin 17 | Q9Y5E5 | DC | Cell–cell interaction | BM | 36 |
| Stromal interaction molecule 2 | Q9P264 | EM and TS1 | Macrophage activation, chemotactic cell migration, activation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells | BM, CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and placenta | 36 and 67 |
| Transporter SLC6A2 | H3BM11 | DC | Sodium-dependent noradrenaline transporter and bone remodeling | Placenta (RNA) | 36 and 68 |

Note: DC = direct contact; EM = expansion medium; WJ-CM = WJ-MSCs–conditioned medium; TS1 = upper of transwell system; TS2 = bottom of transwell system; BM = bone marrow; WJ-MSCs = Wharton’s jelly mesenchymal stem cells.
Colonies Forming Capacity of HSPCs Expanded in the DC Condition

We assessed the ability of CD34⁺ progenitor cells localized in the 2 compartments of the DC system to develop different types of colonies in 6 of the total 12 UCB samples. A higher proportion of primitive colonies, (CFU-GM) and erythroid colonies (BFU-E), was developed from cells of the adherent fraction (P value = 0.007) compared to the cells of the respective floating ones (Table 2). Moreover, the most primitive colonies, GEMM colonies (CFU-GEMM) even if represented at very low frequencies in unmanipulated UCB samples (about 1% over the total colonies developed), also exhibited a trend of increase in the adherent cell fraction compared to the floating one (on average 3.5% vs. 0.5%, respectively).

A further confirmation that adherent CD34⁺ cells are more primitive HSPCs comes from the analysis of BFU-E colony size. The frequency of intermediate/large BFU-E colonies (that consisted of more than 7 clusters) over the total BFU-E colonies was significantly increased in the hematopoietic cells plated from the CD34⁺ cells adherent to the WJ-MSCs with respect to the floating cell fraction (37.0 ± 14.7 vs. 19.0 ± 6.3, respectively, P = 0.013; Table 2).

Proteomic Analysis of Conditioned Media

In order to identify molecular players involved in the cross-talk between CD34⁺ cells and WJ-MSCs, we analyzed the secretome of different culture media by HPLC-MS/MS. Notably, in our analyses, we did not consider the presence of SCF and FLT-3 ligand, since these cytokines are components of the EM used in all conditions. We identified 166 proteins in the EM, 154 proteins in the upper compartment of the transwell coculture system (TS1), 114 proteins in the lower compartment of the transwell coculture system (TS2), 133 proteins in the DC, and 105 proteins in the WJ-CM. The TS medium was analyzed both in the upper and lower compartments in order to discriminate molecules that may be distinctively produced by hematopoietic and/or stromal cells, therefore not passing through the pores of the transwell PET membrane for different reasons such as extracellular deposition.

Since our experiments showed that the CD34⁺ cells can establish different interactions with WJ-MSCs (i.e., the presence of an adherent and a floating cell fraction within DC), we focused our analysis on extracellular proteins that can recreate in vitro a microenvironment similar to that of a hematopoietic niche. We highlighted the presence of 30 extracellular/exosomal or membrane proteins, listed in Table 3, and we performed a comparative analysis among tested culture conditions to investigate the expression differences. Interestingly, in the DC secretome, we identified a set of 16 exclusively expressed proteins. Only some of them were already described in any of the known hematopoietic niches, either prenatal or adult, with most data coming from studies on BM.

Structural molecules with cytoadhesive roles such as collagens, namely, types I, III, and VI, were detected in the secretome of the WJ-MSCs in the 2 coculture conditions (DC and TS2). Confirming the data of ICC analyses shown before, here for the first time, we report the presence of fibronectin as player in cross talk with HSPCs. In fact, secretomic data have allowed detection of fibronectin expression in WJ-CM, DC, and TS2.

Interestingly, specifically in the DC system, we found for the first time the expression of Frem3 a molecule involved in cell adhesion reported to be expressed in BM. We also detected in the DC, WJ-CM, TS2 systems, tissue inhibitor of metalloproteinases-1 (TIMP-1) a protein directly involved in the finely regulated remodeling of the BM extracellular matrix. We detected for the first time specifically in the DC condition the z-fetoprotein, well known to be expressed in in vivo prenatal hematopoietic niches.

Here, we report for the first time the presence of lactotransferrin (iron binding and multifunction protein) in the DC system.

Serine carboxypeptidase-1 (SCPEP1) is a secreted serine protease which has been implicated in monopoiesis. Interestingly, in our system, this molecule was expressed only in the DC secretome. We are the first to show SCPEP1 expression by human WJ-MSCs because only one literature report (to the best of our knowledge) demonstrated its expression in porcine WJ-MSCs.

Wnt-4 and Wnt-6 are part of the recently discovered noncanonical Wnt-Ca²⁺ pathway which is active in hematopoiesis. No data are present in literature on the expression of these molecules in coculture systems with WJ-MSCs. Here, we demonstrated that Wnt-4 was specifically found in TS1, while Wnt-6 was present in the DC secretome. Noteworthy in the DC system, we identified the presence of Notch2. Wnt and Notch signaling are integrated and are selectively active in regulating hemopoiesis and have been implicated in erithropoiesis and in supporting ex vivo expansion of HSPCs. Transforming growth factor-beta (TGF-β) pathways are involved in the regulation of the HSPC homeostasis. Interestingly, we found the TGF-β induced protein H3 (BIGH3) in the DC and WJ-CM secretomes.

Moreover, we detected the secreted molecule z-2 HS glycoprotein (Fetuin A) in all the tested coculture conditions. Importantly, this molecule binds several growth factors (such as TGF-β) regulating their access to surface receptors. Finally, CD109 is a glycosylphosphatidylinositol-anchored glycoprotein that binds the TGF-β receptor. Here, we showed that CD109 was detected only in the DC culture system (Table 3).

Discussion

In the present article, we investigated how WJ-MSCs or their soluble factors influenced the kinetics of UCB-HSPC expansion and which type of hematopoietic subpopulations was
amplified in vitro. Our experiments were performed in a relatively short time to avoid extensive manipulation of HSPCs in order to set ex vivo expansion protocols suitable for future clinical applications.

Our data showed that the DC system sustained a greater CD34+ cell expansion rate with respect to the other tested conditions. Moreover, we here report for the first time that

i. CD34+ cells interacted with WJ-MSCs in different fashions allowing the detection of a floating and an adherent fraction;

ii. WJ-MSCs polymerized an intricate fibronectin-rich network, directing the arrangement of the CD34+ cells and providing a microenvironment which favored the interaction between the 2 cell types;

iii. the DC system recapitulates some functional aspects of a hematopoietic niche. In fact, it is able to expand a component of primitive cells, with phenotypic features typical of long-term repopulating cells, and also to greatly increase the number of lineage-committed shorter-term repopulating cells.

These results are relevant for the outcome of hematopoietic stem cell transplantation.

In fact, the more primitive cells have been linked to the long-term engraftment of a transplant, while an expansion product with more mature committed progenitors and mature cells will be needed to facilitate engraftment to a clinically relevant degree69.

In addition, adherent CD34+ cells were able to develop a higher frequency of primitive colonies, CFU-GM and large BFU-E, and also of the most primitive CFU-GEMM in comparison to the floating cells.

Relevant to these results, we observed a rare hematopoietic stem cell (HSC) population (identified by other authors70 for the coexpression of CD34/CD90 and CD49f and the lack of CD38 and CD45RA) that was more represented in the adherent cell fraction (unpublished observation).

It is important to note that we showed that the WJ-CM also promoted the ex vivo expansion of CD34+ cells, even if to a lesser extent than the cell–cell contact system. In particular, WJ-CM sustained the growth of multipotent hematopoietic progenitors. This finding can be relevant in clinical translation. Further experiments will be needed to better scale up and define this system.

Overall, these functional data revealed that both WJ-MSCs and their soluble factors may be important tools to increase the number of UCB-CD34+ cells in ex vivo systems.

WJ-MSCs physiologically contribute to create the micro-environments that sustain hematopoiesis during the embryonic and fetal period of life. A better characterization of factors produced by WJ-MSCs in the different culture systems may therefore provide important insights on the future expansion strategies employed for UCB-derived CD34+ cells.

The secretomic analysis of the different tested culture conditions revealed the presence of specific molecules that may be potentially be involved in the observed supporting effects on CD34+ cell expansion. The polymerization of an active extracellular matrix already suggested by fibronectin immunolocalization is further validated by the identification of several other adhesion molecules, such as collagens type I, III, and VI, which were consistently found in the DC condition. These molecules together with fibronectin and SPARC are known to be part of the BM and UC and placental hematopoietic niches29,31–33,46,47.

We also found proteins expressed in prenatal hematopoietic sites such as yolk sac and fetal liver and involved in hematopoiesis, namely alpha-fetoprotein (AFP) and lactotransferrin. It is also important to note that it has been reported that MSC-derived AFP prevents apoptosis of HSPCs by cooperating with SCF26.

Wnt signaling pathway molecules were also found in our coculture system. In hematopoietic cells, Wnt proteins may function as proliferation-inducing growth factors, and also affect cell-fate decisions, similar to true morphogens in other systems54,55.

Interestingly, a number of TGF-β interacting molecules (BIGH3, Fetuin A, and CD109) were found in the secretomes of our coculture system. Multiple reports have shown that TGF-β members regulate tissue homeostasis and regeneration. With respect to hematopoiesis, TGF-β plays an important role in regulating HSPC behavior, particularly regarding quiescence and self-renewal71. BIGH3 has been reported to be part of the hematopoietic niche in GC as a modulator of HSPC adhesion and migration, competing for fibronectin binding sites in adhesion assays. BIGH3 may be essential to loosen the contacts of HSCs with tissues such as yolk sac and fetal liver and involved in hematopoiesis, namely alpha-fetoprotein (AFP) and lactotransferrin. It is also important to note that it has been reported that MSC-derived AFP prevents apoptosis of HSPCs by cooperating with SCF26.

Fetuin A is known to be expressed in embryonic/fetal tissues (such as fetal liver). In addition to its known role in binding TGF-β receptor, CD109 was reported as part of the exosomal fraction. Moreover, a secreted furin-cleaved CD109 fragment can modulate TGF-β signaling in adjacent cells58. It is particularly intriguing that negative regulators of TGF-β activity, such as fetuin A and CD109, are expressed in this in vitro expansion system and specifically in the DC culture. Therefore, present data suggest that regulation of the TGF-β pathways may in part explain the results obtained so far in our DC system.

Conclusion

Our results showed that both WJ-MSCs and their conditioned medium are capable of sustaining in vitro hematopoiesis and can be used as a tool to promote HSPC expansion for clinical applications. We also provided insights on the possible mechanisms behind the hematopoiesis support
function of WJ-MSCs. Interestingly, the secretomic analysis showed that the molecules expressed in the DC system recapitulated a functional niche-like hematopoietic microenvironment, a finding further supported by morphological analyses reported here. We highlighted that the DC system specifically provides the expansion of either multipotent or committed progenitor cells, both essential for the outcome of HSPC transplantation. To this end, clinical trials already demonstrated that co-transplantation of UCB-HSPCs and WJ-MSCs generates a superior graft with respect to UCB alone, as reviewed in Reference 9. Further studies are needed to better delineate the roles of the molecular players that we identified in our experiments.

Acknowledgments
We thank Domenica Abbate and the whole team of obstetrics and gynecology division, Villa Sofia-Cervello Hospital, for the excellent assistance provided. We also thank Drs. Francesca Raiata and Aroldo Rizzo, from the Pathologic Anatomy Service, Villa Sofia-Cervello Hospital, for the assistance in immunocytochemical analyses.

Ethical Approval
This study was approved by our institutional review board. Approval case numbers no. 124 (01-12-2010) and no.331 (8-11.2016).

Statement of Human and Animal Rights
Human rights were treated in accordance with the tenets of the Declaration of Helsinki and local ethical regulations.

Statement of Informed Consent
Human samples were obtained after acquiring written informed consent from the mothers.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Giampiero La Rocca is a member of the Scientific Board of Auxocell Laboratories, Inc. The other authors declare no potential conflicts of interest.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Part of this work was performed using instruments provided by the Euro-Mediterranean Institute of Science and Technology and funded by the Italian National Operational Programme for Research and Competitiveness 2007-2013 grant (project code: PONa3_00210; European Regional Development Fund).

References
1. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013; 122(4):491–498.
2. Cohen Y, Nagler A. Umbilical cord blood transplantation-how, when and for whom? Blood. 2004;18(3):167–179.
3. Kita K, Lee JO, Finnerty CC, Herndon DN. Cord blood-derived hematopoietic stem/progenitor cells: current challenges in engraftment, infection, and ex vivo expansion. Stem Cells Int. 2011;2011:276193.
4. Bari S, Seh K, Poon Z, Cheun AM, Fan X, Ong SY, Li S, Koh LP, Hwang WY. Expansion and homing of umbilical cord blood hematopoietic stem and progenitor cells for clinical transplantation. Biol Blood Marrow Transplant. 2015;21(6):1008–1019.
5. Wagner W, Weina F, Roderburga C. Adhesion of hematopoietic progenitor cells to human mesenchymal stem cells as a model for cell-to-cell interaction. Exp Hematol. 2007;35(2):314–325.
6. Oh IH, Kwon KR. Concise review: multiple niches for hematopoietic stem cell regulation. Stem Cell. 2010;28(7):1243–1249.
7. Wagner W, Roderburg C, Wein F, Diehlmann A, Frankhauser M, Schubert R, Eckstein V, Ho AD. Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. Stem Cells. 2007;25(10):2638–2647.
8. Morrison SJ, Scadden DT. The bone marrow niche for hematopoietic stem cells. Nature. 2014;505(7483):327–334.
9. Lo Iacono M, Anzalone R, La Rocca G, Baiamonte E, Maggio A, Acuto S. Wharton’s jelly mesenchymal stem cells as a feeder layer for the ex vivo expansion of hematopoietic stem and progenitor cells: a review. Stem Cell Rev. 2017;13(1):35–49.
10. Fajardo-Orduna GR, Mayani H, Montesinos JJ. Hematopoietic support capacity of mesenchymal stem cells: biology and clinical potential. Arch Med Res. 2015;46(8):589–596.
11. Corrao S, La Rocca G, Lo Iacono M, Corsello T, Farina F, Anzalone R. Umbilical cord revisited: From Wharton’s jelly myofibroblasts to mesenchymal stem cells. Histol Histopathol. 2013;28(10):1235–1244.
12. Mikkola IK, Gekas C, Orkin SH, Dieterlen-Lievre F. Placenta as a site for hematopoietic stem cell development. Exp Hematol. 2005;33(9):1048–1054.
13. Troyer DL, Weiss ML. Concise review: Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells. 2007;26(3):591–599.
14. Lu LL, Liu YJ, Yang SG. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91(8):1017–1026.
15. Friedman R, Betancur M, Boissel L, Tuncer H, Cetrulo C, Klingermann H. Umbilical cord mesenchymal stem cells: advantages for human cell transplantation. Biol Blood Marrow Transplant. 2007;13(12):1477–1486.
16. Gadue P, Weiss MJ. Stem cells unscramble yolk sac hematopoiesis. Blood. 2009;114(8):1455–1456.
17. Robin C, Bollerot K, Mendes S, Haak E, Crisan M, Cerisoli F, Lauw I, Kaimakis P, Jorna R, Vermeulen M, et al. Human placenta is a potent hematopoietic niche containing hematopoietic stem and progenitor cells throughout development. Cell Stem Cell. 2009;5(4):385–395.
18. La Rocca G, Anzalone R, Corrao S, Magno F, Loria T, Lo Iacon M, Di Stefano A, Giannuzzi P, Marasà L, Cappello F, et al. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochim Cell Biol. 2009;131(2):267–282.

19. La Rocca, Lo Iacono M, Corsello T, Corrao S, Farina F, Anzalone R. Human Wharton’s jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy. Curr Stem Cell Res Ther. 2013;8(1):100–113.

20. Fong CY, Gauthaman K, Cheyyatraivendran S, Lin HD, Biswas A, Bongso A. Human umbilical cord Wharton’s jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo. J Cell Biochem. 2012;113(2):658–668.

21. Dellagi K, Vainchenker W, Vinci G, Paulin D, Brouet JC. Alteration of vimentin intermediate filament expression during differentiation of human hemopoietic cells. EMBO J. 1983;2(9):1509–1514.

22. Mosaad YM. Hematopoietic stem cells: an overview. Transfus Apher Sci. 2014;51(3):68–82.

23. Jing D, Fonseca AV, Alakel N, Fiero FA, Muller K, Bornhauser M, Ehninger G, Corbeli D, Ordemann R. Hematopoietic stem cells in co-culture with mesenchymal stromal cells-modeling the niche compartments in vitro. Hematologica. 2010;95(4):542–550.

24. Nandadasa S, Nelson CM, Apte SS. ADAMTS9-mediated extracellular matrix dynamics regulates umbilical cord vascular smooth muscle differentiation and rotation. Cell Rep. 2015;11(10):1519–1528.

25. Newby D, Dalgliesh G, Lyall F, Aitken DA. Alphaetaprotein and alphaetaprotein receptor expression in the normal human placenta at term. Placenta. 2005;26(2-3):190–200.

26. Bartha JL, Romero-Carmona R, Comino-Delgado R, Arce F, Arraball J. Alphaetaprotein and hematopoietic growth factors in amniotic fluid. Obstet Gynecol. 2000;96(4):588–592.

27. Szwerais M, Liu D, Partridge EA, Pawling J, Sukhu B, Clokie MR, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.

28. Siebertz B, Stöcker G, Drzeniek Z, Handt S, Just U, Haubeck HD. Expression of gypican-4 in haematopoietic-progenitor and bone-marrow-stromal cells. Biochem J. 1999;344(Pt 3):937–943.

29. Manjili MH, Park JE, Facciponte JG, Wang XY, Subjeck JR. Immunoadjuvant chaperone, GRP170, induces ‘danger signals’ upon interaction with dendritic cells. Immunol Cell Biol. 2006;84(2):203–208.

30. Artyom J, Zimecki M. The effects of lactoferrin on myelopoiesis: can we resolve the controversy? Postepy Hig Med Dosw (Online). 2007;61:129–150.

31. Ward PP, Mendoza-Meneses M, Mulac-Jericevic B, Cunningham GA, Saucedo-Cardenas O, Teng CT, Conneely OM. Restricted spatiotemporal expression of lactoferrin during murine embryonic development. Endocrinology. 1999;140(4):1852–1860.

32. Niemelä Å, Kulomaa M, Vija P, Tuohimaa P, Saarikoski S. Lactoferrin in human amniotic fluid. Hum Reprod. 1989;4(1):99–101.

33. Steinl C, Essl M, Schreiber TD, Geiger K, Prokop L, Stevanović S, Pötz O, Abele H, Wessels JT, Aicher WK, et al. Release of matrix metalloproteinase-8 during physiological trafficking and induced mobilization of human hematopoietic stem cells. Stem Cells. 2013;32(9):1307–1318.

34. Ibrahim AA, Yahata T, Onizuka M, Dan T, Van Ypersele De Strihou C, Miyata T, Ando K. Inhibition of plasminogen activator inhibitor type-1 activity enhances rapid and sustainable hematopoietic regeneration. Stem Cells. 2014;32(4):946–958.

35. Mello FV, Alves LR, Land MG, Teodósio C, Sanchez ML, Barcena P, Peres RT, Pedreira CE, Costa ES, Orfao A. Maturation-associated gene expression profiles along normal human bone marrow monopoiesis. Br J Haematol. 2017;176(3):464–474.

36. Huang L, Niu C, Willard B, Zhao W, Liu L, He W, Wu T, Yang S, Feng S, Mu Y, et al. Proteomic analysis of porcine mesenchymal stem cells derived from bone marrow and umbilical cord: implication of the proteins involved in the higher migration capability of bone marrow mesenchymal stem cells. Stem Cell Res Ther. 2015;6(1):77.

37. Luo Z, Zhou Y, Luo P, Zhao Q, Xiao N, Yu Y, Yan Q, Lu G, Cheng L. SPARC deficiency affects bone marrow stromal...
function, resulting in impaired B lymphopoiesis. J Leukoc Biol. 2014;96(1):73–82.
47. Luo Z, Luo P, Yu Y, Zhao Q, Zhao X, Cheng L. SPARC promotes the development of erythroid progenitors. Exp Hematol. 2012;40(10):828–836.
48. Sobolewski K, Malkowski A, Bańkowski E, Jaworski S. Wharton’s jelly as a reservoir of peptide growth factors. Placenta. 2005;26(10):747–752.
49. Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. 2014;71(4):659–672.
50. Deng CL, Ling ST, Liu XQ, Zhao YJ, Lv YF. Decreased expression of matrix metalloproteinase-1 in the maternal umbilical serum, trophoblasts and decidua leads to preeclampsia. Exp Ther Med. 2015;9(3):992–998.
51. Klamer SE, Kuijk CG, Hordijk PL, van der Schoot CE, von Lindern M, van Hennik PB, Voermans C. The role of novel and known extracellular matrix and adhesion molecules in the homeostatic and regenerative bone marrow microenvironment. Cell Adh Migr. 2014;8(6):563–577.
52. Billings PC, Whitbeck JC, Adams CS, Abrams WR, Cohen AJ, Engelsberg BN, Howard PS, Rosenbloom J. The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin. J Biol Chem. 2002;277(31):28003–28009.
53. Kokolus K, Nemeth MJ. Non-canonical Wnt signaling pathways in hematopoiesis. Immunol Res. 2010;46(1-3):155–164.
54. Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol. 2008;8(8):581–593.
55. Schaale K, Brandenburg J, Kispert A, Leitges M, Ehlers S, Reiling N. Wnt6 is expressed in granulomatous lesions of Mycobacterium tuberculosis-infected mice and is involved in macrophage differentiation and proliferation. J Immunol. 2013;191(10):5182–5195.
56. Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, Yeo EL, Schulz AC, Sutherland DR. CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol. 1999;27(8):1282–1294.
57. Yokoyama M, Ichinoe M, Okina S, Sakurai Y, Nakada N, Yanagisawa N, Jiang SX, Numata Y, Umezawa A, Miyazaki K, et al. CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma. Int J Hematol. 2017;105(5):614–622.
58. Schofield KP, Humphries MJ, de Wynter E, Testa N, Gallagher JT. The effect of alpha4 beta1-integrin binding sequences of fibronectin on growth of cells from human hematopoietic progenitors. Blood. 1998;91(9):3230–3238.
59. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23 R. J Immunol. 2002;168(11):5699–5708.
60. Li H, Yue R, Wei B, Gao G, Du J, Pei G. Lysophosphatidic acid acts as a nutrient-derived developmental cue to regulate early hematopoiesis. EMBO J. 2014;33(12):1383–1396.
61. Kostic I, Fidalgo-Carvalho I, Aday S, Vazão H, Carvalheiro T, Grãos M, Duarte A, Cardoso C, Gonçalves L, Carvalho L, et al. Lysophosphatidic acid enhances survival of human CD34(+) cells in ischemic conditions. Sci Rep. 2015;5:16406.
62. Oh P, Lobry C, Gao J, Tikhonova A, Loizou E, Manent J, van Handel B, Ibrahim S, Greve J, Mikkola H, et al. In vivo mapping of notch pathway activity in normal and stress hematopoiesis. Cell Stem Cell. 2013;13(2):190–204.
63. Carlesso N, Aster JC, Sklar J, Scadden DT. Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Blood. 1999;93(3):838–848.
64. Karanu FN, Murdoch B, Gallacher L, Wu DM, Koremoto M, Sakano S, Bhatia M. The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells. J Exp Med. 2000;192(9):1365–1372.
65. Sarker S, Scholz-Romero K, Perez A, Illanes SE, Mitchell MD, Rice GE, Salomon C. Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J Transl Med. 2014;12(1):204.
66. Sogkas G, Stegner D, Syed SN, Vogtle T, Rau E, Gewecke B, Schmidt RE, Nieswandt B, Gessner JE. Cooperative and alternate functions for STIM1 and STIM2 in macrophage activation and in the context of inflammation. Immun Inflamm Dis. 2015;3(3):154–170.
67. Vähäkangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol. 2009;158(3):665–678.
68. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, Bearman SI, Nieto Y, Freed B, Madinger N, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant. 2002;8(7):368–376.
69. Notta F, Doulatov S, Laurenti E, Pflanz S, Zhang R, Singh KP, Vega F, et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science. 2011;333(6039):218–221.
70. Blank U, Karlsson S. TGF-β signaling in the control of hematopoietic stem cells. Blood. 2015;125(23):3542–3550.